Primary immune thrombocytopenia (ITP) is rare. First-line treatment is corticotherapy. Then, several second-line treatments (SLT) are available: splenectomy, off-label rituximab and thrombopoietin-receptor agonists since 2009. The compared efficacy and safety on clinical events in the long-term are unknown. The main objective of the FAITH study is to build the cohort of all treated adult persistent (≥3 months) primary ITP patients in France, to assess the benefit-to-risk ratio of SLT in real-life practice. Data source is the database of French Health Insurance System (SNIIRAM) which covers the entire French population. It collects demographic, chronic disease, hospitalization and drug dispensing data. All patients with ITP were extracted from 2009 to 2012, and then every year for 10 years. The investigator will build the cohort from raw data. Outcomes (death, hospitalization, drug dispensing) will be compared according to SLT, with controls from the general population and untreated patients.
Study Type
OBSERVATIONAL
Enrollment
10,000
The information collected are about : * Introduction or non-introduction of treatment * Cumulative dose of treatment * Drug dispensation and withdrawal * Hospitalization reason * Safety information * Demographic data (date of death)
University Hospital of Toulouse
Toulouse, France
RECRUITINGExposition or non exposition to available immune thrombocytopenia persistent
Data will be extracted until the end of study
Time frame: up to 10 years
Mortality as assessed date of death collected in the database
Data will be extracted every year of the study until the end of study
Time frame: Each year until 10 years
Number of hospitalization for bleeding in the database
Number of hospitalization for bleeding will be extract from database every year
Time frame: Each year until 10 years
Safety of treatment for infections
Number of infections is represented by number of hospitalization and antibiotics dispensation and will be extract from database every year
Time frame: Each year until 10 years
Safety of treatment for cardio-vascular events
Number of hospitalization for cardio-vascular events will be extract from database every year
Time frame: Each year until 10 years
Safety of treatment for thrombo-embolic events
Number of hospitalization for thrombo-embolic events will be extract from database every year
Time frame: Each year until 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.